Posterior corneal curvature changes in patients with keratoconus
Session Details
Session Title: Corneal Biomechanics
Session Date/Time: Sunday 15/09/2019 | 16:30-18:00
Paper Time: 17:18
Venue: Free Paper Forum: Podium 4
First Author: : N.Menassa UK
Co Author(s): : M. Brunner C. de Lossada D. Borroni G. Czanner S. Kaye V. Romano
Abstract Details
Purpose:
To investigate a method for precision analysis to discriminate corneal change from measurement imprecision in patients with keratoconus (KC).
Setting:
St. Paul's Eye Unit,
Royal Liverpool University Hospital,
Liverpool,
United Kingdom
Methods:
Patients with KC and healthy controls were included in a prospective study. Posterior corneal tomographic parameters using a Pentacam HR were analysed. Patients had 3 measurements undertaken on 2 occasions. Coefficients of repeatability and limits of agreement (LOA) were compared using single and multiple measurements for each observer. Correlation of repeated measurements was evaluated using a linear mixed effect model. A formula was derived for the theoretical expected change in precision and compared with measured change.
Results:
Sixty eyes of sixty patients were included: 30 healthy subjects (mean age 31.6±10 years) and 30 patients with KC (mean age 26.7±8 years). High quality scans were achieved in all healthy eyes (180 scans) and in 91.7% of the keratoconic eyes (165 scans). Posterior corneal curvature values were significantly higher in the KC group (p<0.01). Intra- and inter-observer 95% and 99.73% limits of agreement (LOA) for K1 flat [D], K2 steep [D], K mean [D], and K2-K1 [D] in healthy and keratoconic eyes showed 99.73% LOA using mean of 3 measurements were narrower than one-measurement 95% LOA.
Conclusions:
The 99.73% LOA (3 SD) using the mean of three measurements, provides better precision than 95% LOA (2 SD) using a single measure. A change in the back surface of the cornea of more than 0.21D K1 or 0.17D K2 using the mean of 3 measurements can be used as a cut-off for change in the back surface of the cornea in patients with KC.
Financial Disclosure:
None